Trial reportPloS one2014
Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma.
Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00712790 (Phase I/II Study of SIR-Spheres Plus Sorafenib as First Line Treatment in Patients With Non-Resectable Primary Hepatocellular Carcinoma), which is not on this map. Cited by 34 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I/II Study of SIR-Spheres Plus Sorafenib as First Line Treatment in Patients With Non-Resectable Primary Hepatocellular Carcinoma
Who cites it
34 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Phase I-IV Drug Trials on Hepatocellular Carcinoma in Asian Populations: A Systematic Review of Ten Years of Studies.International journal of molecular sciences · 2024Pooled it
- Health-related quality of life in primary hepatic cancer: a systematic review assessing the methodological properties of instruments and a meta-analysis comparing treatment strategies.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021Pooled it
- Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review.PLoS biology · 2017Pooled it
- Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions.The British journal of radiology · 2015Pooled it
- Quality of life in patients with liver tumors treated with holmium-166 radioembolization.Clinical & experimental metastasis · 2020Trial
- Prevalence of gastrointestinal side effects in hepatocellular carcinoma patients receiving sorafenib: a meta-analysis of 136 studies and 14,416 patients.Therapeutic advances in medical oncology · 2026Article
- Prediction of hepatocellular carcinoma response to radiation segmentectomy using an MRI-based machine learning approach.Abdominal radiology (New York) · 2025Article
- Hepatocellular Carcinoma and Health-Related Quality of Life: A Systematic Review of Outcomes From Systemic Therapies.International journal of hepatology · 2025Article
- Applications of Yttrium-90 (OncoTargets and therapy · 2024Review
- Emerging Trends in the Treatment of Advanced Hepatocellular Carcinoma: A Radiological Perspective.Korean journal of radiology · 2021Review
- Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial.JMIR research protocols · 2018Article
- Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus.Journal of gastrointestinal oncology · 2017Review
- Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma.Current treatment options in oncology · 2017Review
- New concepts in embolotherapy of HCC.Medical oncology (Northwood, London, England) · 2017Review
- Selective internal radiation therapy with SIR-Spheres in hepatocellular carcinoma and cholangiocarcinoma.Journal of gastrointestinal oncology · 2017Review
- Article
- Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry.The British journal of radiology · 2016Review
- Current status of transarterial radioembolization.World journal of radiology · 2016Review
- National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma.Liver cancer · 2016Article
- Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review.World journal of gastroenterology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe safety and tolerability of sequential radioembolization-sorafenib therapy is unknown. An open-label, single arm, investigator-initiated Phase II study (NCT0071279) was conducted at four Asia-Pacific centers to evaluate the safety and efficacy of sequential radioembolization-sorafenib in patients with hepatocellular carcinoma (HCC) not amenable to curative therapies.
methodsSorafenib (400 mg twice-daily) was initiated 14 days post-radioembolization with yttrium-90 (90Y) resin microspheres given as a single procedure. The primary endpoints were safety and tolerability and best overall response rate (ORR) using RECIST v1.0.Secondary endpoints included: disease control rate (complete [CR] plus partial responses [PR] and stable disease [SD]) and overall survival (OS).
resultsTwenty-nine patients with Barcelona Clinic Liver Cancer (BCLC) stage B (38%) or C (62%) HCC received a median of 3.0 GBq (interquartile range, 1.0) 90Y-microspheres followed by sorafenib (median dose/day, 600.0 mg; median duration, 4.1 months). Twenty eight patients experienced ≥1 toxicity; 15 (52%) grade ≥3. Best ORR was 25%, including 2 (7%) CR and 5 (18%) PR, and 15 (54%) SD. Disease control was 100% and 65% in BCLC stage B and C, respectively. Two patients (7%) had sufficient response to enable radical therapy. Median survivals for BCLC stage B and C were 20.3 and 8.6 months, respectively.
conclusionsThis study shows the potential efficacy and manageable toxicity of sequential radioembolization-sorafenib.
trial registrationClinicalTrials.gov NCT00712790.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.